All-In ft. Vivek Ramaswamy

Vivek Ramaswamy says

Big pharma companies would not take risks unless everyone else was taking the same risks, because taking a different risk and failing meant budget cuts, job security risks and social embarrassment, while failing alongside everyone else was safe. He built a company, Roivant, that in licensed drugs in their early phase one or phase two stages, often for pennies on the dollar relative to what had already been invested in them. He led the company as CEO for seven years, five of the drugs he worked on are FDA approved today, it became a 10 billion dollar public company, and it returned over a billion dollars to shareholders before going public.

Try this

Identify one asset or project a competitor dropped for reputational rather than scientific reasons and evaluate acquiring it cheaply.